Histone deacetylase inhibitor pracinostat in doublet therapy: a unique strategy to improve therapeutic efficacy and to tackle herculean cancer chemoresistance

Pharmaceutical Biology

Volumn 54, Issue 9, 2016, Pages 1926-1935

  Ganai, Shabir Ahmad ^a  

^a SHER E KASHMIR UNIVERSITY OF AGRICULTURAL SCIENCES AND TECHNOLOGY OF KASHMIR   (India)

Author keywords

Apoptosis; histone acetyl transferases; pacritnib; therapeutic intervention

Indexed keywords

PRACINOSTAT; VORINOSTAT; ANTINEOPLASTIC AGENT; BENZIMIDAZOLE DERIVATIVE; HISTONE DEACETYLASE INHIBITOR; SB939 COMPOUND;

ACUTE MYELOBLASTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; CANCER RESISTANCE; CHRONIC MYELOID LEUKEMIA; CLINICAL EFFECTIVENESS; COLORECTAL CANCER; DATA ANALYSIS; DRUG CLASSIFICATION; DRUG CYTOTOXICITY; DRUG DETERMINATION; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG STRUCTURE; HEMATOLOGIC MALIGNANCY; HUMAN; MOLECULAR DYNAMICS; NONHUMAN; OUTCOME ASSESSMENT; PHYSICAL PARAMETERS; REVIEW; SOLID TUMOR; ANIMAL; DRUG RESISTANCE; ENZYMOLOGY; MORTALITY; NEOPLASMS; PATHOLOGY; TREATMENT OUTCOME;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZIMIDAZOLES; DRUG RESISTANCE, NEOPLASM; HISTONE DEACETYLASE INHIBITORS; HUMANS; NEOPLASMS; TREATMENT OUTCOME;

EID: 84958544900     PISSN: 13880209     EISSN: 17445116     Source Type: Journal    
DOI: 10.3109/13880209.2015.1135966     Document Type: Review

References (69)

1. A.J.Bannister, T.Kouzarides 2011. Regulation of chromatin by histone modifications. Cell Res. 21:381–395.
2. L.Bastian, J.Hof, M.Pfau, I.Fichtner, C.Eckert, G.Henze, J.Prada, A.von Stackelberg, K.Seeger, S.Shalapour. 2013. Synergistic activity of bortezomib and HDACi in preclinical models of B-cell precursor acute lymphoblastic leukemia via modulation of p53, PI3K/AKT, and NF-kappaB. Clin Cancer Res. 19:1445–1457.
3. M.P.Bhuiyan, T.Kato, T.Okauchi, N.Nishino, S.Maeda, T.G.Nishino, M.Yoshida. 2006. Chlamydocin analogs bearing carbonyl group as possible ligand toward zinc atom in histone deacetylases. Bioorg Med Chem. 14:3438–3446.
4. A.V.Bieliauskas, M.K.H.Pflum 2008. Isoform-selective histone deacetylase inhibitors. Chem Soc Rev. 37:1402–1413.
5. D.Buglio, G.V.Georgakis, S.Hanabuchi, K.Arima, N.M.Khaskhely, Y.J.Liu, A.Younes. 2008. Vorinostat inhibits STAT6-mediated TH2 cytokine and TARC production and induces cell death in Hodgkin lymphoma cell lines. Blood. 112:1424–1433.
6. D.J.Cao, Z.V.Wang, P.K.Battiprolu, N.Jiang, C.R.Morales, Y.Kong, B.A.Rothermel, T.G.Gillette, J.A.Hill. 2011. Histone deacetylase (HDAC) inhibitors attenuate cardiac hypertrophy by suppressing autophagy. Proc Natl Acad Sci USA. 108:4123–4128.
7. A.Carrato 2008. Adjuvant treatment of colorectal cancer. Gastrointest Cancer Res. 2:S42–S46.
8. T.C.Chou, P.Talalay 1984. Quantitative analysis of dose-effect relationships:the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 22:27–55.
9. P.Chun 2015. Histone deacetylase inhibitors in hematological malignancies and solid tumors. Arch Pharm Res. 38:933–949.
10. U.Cobanoglu, M.Sonmez, H.M.Ozbas, N.Erkut, G.Can. 2010. The expression of LMO2 protein in acute B-cell and myeloid leukemia. Hematology. 15:132–134.
11. C.Colussi, C.Mozzetta, A.Gurtner, B.Illi, J.Rosati, S.Straino, G.Ragone, M.Pescatori, G.Zaccagnini, A.Antonini, et al. 2008. HDAC2 blockade by nitric oxide and histone deacetylase inhibitors reveals a common target in Duchenne muscular dystrophy treatment. Proc Natl Acad Sci USA. 105:19183–19187.
12. J.E.Cortes, H.Kantarjian, N.P.Shah, D.Bixby, M.J.Mauro, I.Flinn, T.O'Hare, S.Hu, N.I.Narasimhan, V.M.Rivera, et al. 2012. Ponatinib in refractory philadelphia chromosome-positive leukemias. N Engl J Med. 367:2075–2088.
13. A.J.de Ruijter, A.H.van Gennip, H.N.Caron, S.Kemp, A.B.van Kuilenburg. 2003. Histone deacetylases (HDACs):characterization of the classical HDAC family. Biochem J. 370:737–749.
14. W.Fazzone, P.M.Wilson, M.J.Labonte, H.J.Lenz, R.D.Ladner. 2009. Histone deacetylase inhibitors suppress thymidylate synthase gene expression and synergize with the fluoropyrimidines in colon cancer cells. Int J Cancer. 125:463–473.
15. M.S.Finnin, J.R.Donigian, A.Cohen, V.M.Richon, R.A.Rifkind, P.A.Marks, R.Breslow, N.P.Pavletich. 1999. Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature. 401:188–193.
16. W.Fischle, V.Kiermer, F.Dequiedt, E.Verdin 2001. The emerging role of class II histone deacetylases. Biochem Cell Biol. 79:337–348.
17. A.Galmozzi, N.Mitro, A.Ferrari, E.Gers, F.Gilardi, C.Godio, G.Cermenati, A.Gualerzi, E.Donetti, D.Rotili, et al. 2013. Inhibition of class I histone deacetylases unveils a mitochondrial signature and enhances oxidative metabolism in skeletal muscle and adipose tissue. Diabetes. 62:732–742.
18. S.A.Ganai 2015. HDAC inhibitors entinostat and suberoylanilide hydroxamic acid (SAHA):the ray of hope for cancer therapy. Mole Life Sci. 1–16.
19. S.A.Ganai 2016. Panobinostat:the small molecule metalloenzyme inhibitor with marvelous anticancer activity. Curr Top Med Chem. 16:427–434.
20. S.A.Ganai, S.M.Kalladi, V.Mahadevan 2015. HDAC inhibition through valproic acid modulates the methylation profiles in human embryonic kidney cells. J Biomol Struct Dyn. 33:1185–1197.
21. S.A.Ganai, K.Shanmugam, V.Mahadevan 2015. Energy-optimised pharmacophore approach to identify potential hotspots during inhibition of class II HDAC isoforms. J Biomol Struct Dyn. 33:374–387.
22. A.Gibbs, J.Schwartzman, V.Deng, J.Alumkal. 2009. Sulforaphane destabilizes the androgen receptor in prostate cancer cells by inactivating histone deacetylase 6. Proc Natl Acad Sci USA. 106:16663–16668.
23. G.Garcia-Manero, C.Chuah, G.Wilding, J.Chang, S.Verstovsek, S.Faderl, H.M.Kantarjian, K.Ethirajulu, J.Zhu. 2010. Phase I study of the oral histone deacetylase inhibitor SB939 in patients with advanced hematologic malignancies. Blood 116. Abstract no. 3292.
24. G.Garcia-Manero, E.Atallah, S.K.Khaled, M.Arellano, M.M.Patnaik, T.A.Butler, C.Ashby, B.C.Medeiros. 2015. Updated results from a phase 2 study of pracinostat in combination with azacitidine in elderly patients with acute myeloid leukemia. EHA Annual Congress, Poster.
25. M.Haberland, R.L.Montgomery, E.N.Olson 2009. The many roles of histone deacetylases in development and physiology:implications for disease and therapy. Nat Rev Genet. 10:32–42.
26. S.Hart, K.C.Goh, V.Novotny-Diermayr, C.Y.Hu, H.Hentze, Y.C.Tan, B.Madan, C.Amalini, Y.K.Loh, L.C.Ong, et al. 2011. SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies. Leukemia. 25:1751–1759.
27. S.Hart, K.C.Goh, V.Novotny-Diermayr, Y.C.Tan, B.Madan, C.Amalini, L.C.Ong, B.Kheng, A.Cheong, J.Zhou, et al. 2011. Pacritinib (SB1518), a JAK2/FLT3 inhibitor for the treatment of acute myeloid leukemia. Blood Cancer J. 1:e44.
28. R.Hind, D.R.Rew, C.D.Johnson 1992. Surgical excision alone is adequate treatment for primary colorectal cancer. Ann R Coll Surg Engl. 74:63–67.
29. A.Hochhaus, S.Kreil, A.S.Corbin, P.La Rosee, M.C.Muller, T.Lahaye, B.Hanfstein, C.Schoch, N.C.Cross, U.Berger, et al. 2002. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia. 16:2190–2196.
30. E.Jabbour, H.Kantarjian 2014. Chronic myeloid leukemia:2014 update on diagnosis, monitoring, and management. Am J Hematol. 89:547–556.
31. C.U.Johannessen, S.I.Johannessen 2003. Valproate:past, present, and future. CNS Drug Rev. 9:199–216.
32. J.Jones, E.Juengel, A.Mickuckyte, L.Hudak, S.Wedel, D.Jonas, R.A.Blaheta. 2009. The histone deacetylase inhibitor valproic acid alters growth properties of renal cell carcinoma in vitro and in vivo. J Cell Mol Med. 13:2376–2385.
33. S.Kalyaanamoorthy, Y.P.Chen 2013. Energy based pharmacophore mapping of HDAC inhibitors against class I HDAC enzymes. Biochim Biophys Acta. 1834:317–328.
34. H.Kantarjian, C.Sawyers, A.Hochhaus, F.Guilhot, C.Schiffer, C.Gambacorti-Passerini, D.Niederwieser, D.Resta, R.Capdeville, U.Zoellner, et al. 2002. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med. 346:645–652.
35. H.M.Kantarjian, M.Talpaz, F.Giles, S.O'Brien, J.Cortes. 2006. New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance. Ann Intern Med. 145:913–923.
36. A.G.Kazantsev, L.M.Thompson 2008. Therapeutic application of histone deacetylase inhibitors for central nervous system disorders. Nat Rev Drug Discov. 7:854–868.
37. N.Khan, M.Jeffers, S.Kumar, C.Hackett, F.Boldog, N.Khramtsov, X.Qian, E.Mills, S.C.Berghs, N.Carey, et al. 2008. Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors. Biochem J. 409:581–589.
38. M.Kijima, M.Yoshida, K.Sugita, S.Horinouchi, T.Beppu. 1993. Trapoxin, an antitumor cyclic tetrapeptide, is an irreversible inhibitor of mammalian histone deacetylase. J Biol Chem. 268:22429–22435.
39. H.J.Kim, S.C.Bae 2011. Histone deacetylase inhibitors:molecular mechanisms of action and clinical trials as anti-cancer drugs. Am J Transl Res. 3:166–179.
40. N.Korolev, A.Allahverdi, A.P.Lyubartsev, L.Nordenskiold. 2012. The polyelectrolyte properties of chromatin. Soft Matter. 8:9322–9333.
41. S.K.Kurdistani, M.Grunstein 2003. Histone acetylation and deacetylation in yeast. Nat Rev Mol Cell Biol. 4:276–284.
42. T.Lahaye, B.Riehm, U.Berger, P.Paschka, M.C.Muller, S.Kreil, K.Merx, U.Schwindel, C.Schoch, R.Hehlmann, et al. 2005. Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center:a 4.5-year follow-up. Cancer. 103:1659–1669.
43. F.Leoni, G.Fossati, E.C.Lewis, J.K.Lee, G.Porro, P.Pagani, D.Modena, M.L.Moras, P.Pozzi, L.L.Reznikov, et al. 2005. The histone deacetylase inhibitor ITF2357 reduces production of pro-inflammatory cytokines in vitro and systemic inflammation in vivo. Mol Med. 11:1–15.
44. V.L.Luchenko, C.D.Salcido, Y.Zhang, K.Agama, E.Komlodi-Pasztor, R.F.Murphy, G.Giaccone, Y.Pommier, S.E.Bates, L.Varticovski. 2011. Schedule-dependent synergy of histone deacetylase inhibitors with DNA damaging agents in small cell lung cancer. Cell Cycle. 10:3119–3128.
45. A.Mantovani, P.Allavena, A.Sica, F.Balkwill. 2008. Cancer-related inflammation. Nature. 454:436–444.
46. A.Mantovani, M.A.Pierotti 2008. Cancer and inflammation:a complex relationship. Cancer Lett. 267:180–181.
47. J.Mishra, J.Drummond, S.H.Quazi, S.S.Karanki, J.J.Shaw, B.Chen, N.Kumar. 2013. Prospective of colon cancer treatments and scope for combinatorial approach to enhanced cancer cell apoptosis. Crit Rev Oncol Hematol. 86:232–250.
48. M.Mottamal, S.Zheng, T.L.Huang, G.Wang. 2015. Histone deacetylase inhibitors in clinical studies as templates for new anticancer agents. Molecules. 20:3898–3941.
49. V.Novotny-Diermayr, S.Hart, K.C.Goh, A.Cheong, L.C.Ong, H.Hentze, M.K.Pasha, R.Jayaraman, K.Ethirajulu, J.M.Wood. 2012. The oral HDAC inhibitor pracinostat (SB939) is efficacious and synergistic with the JAK2 inhibitor pacritinib (SB1518) in preclinical models of AML. Blood Cancer J. 2:e69.
50. V.Novotny-Diermayr, K.Sangthongpitag, C.Y.Hu, X.Wu, N.Sausgruber, P.Yeo, G.Greicius, S.Pettersson, A.L.Liang, Y.K.Loh, et al. 2010. SB939, a novel potent and orally active histone deacetylase inhibitor with high tumor exposure and efficacy in mouse models of colorectal cancer. Mol Cancer Ther. 9:642–652.
51. S.J.Nowak, V.G.Corces 2004. Phosphorylation of histone H3:a balancing act between chromosome condensation and transcriptional activation. Trends Genet. 20:214–220.
52. S.Okabe, T.Tauchi, Y.Tanaka, S.Kimura, T.Maekawa, K.Ohyashiki. 2013. Activity of histone deacetylase inhibitors and an Aurora kinase inhibitor in BCR-ABL-expressing leukemia cells:combination of HDAC and Aurora inhibitors in BCR-ABL-expressing cells. Cancer Cell Int. 13:32.
53. L.Peng, E.Seto 2011. Deacetylation of nonhistone proteins by HDACs and the implications in cancer. Handb Exp Pharmacol. 206:39–56.
54. T.Prebet, N.Vey 2011. Vorinostat in acute myeloid leukemia and myelodysplastic syndromes. Expert Opin Investig Drugs. 20:287–295.
55. A.Quintas-Cardama, H.Kantarjian, J.Cortes 2010. Third-generation tyrosine kinase inhibitors and beyond. Semin Hematol. 47:371–380.
56. A.Quintás-Cardama, H.Kantarjian, Z.Estrov, G.Borthakur, J.Cortes, S.Verstovsek. 2012. Therapy with the histone deacetylase inhibitor pracinostat for patients with myelofibrosis. Leuk Res. 36:1124–1127.
57. A.Quintas-Cardama, F.P.Santos, G.Garcia-Manero 2011. Histone deacetylase inhibitors for the treatment of myelodysplastic syndrome and acute myeloid leukemia. Leukemia. 25:226–235.
58. A.R.A.Razak, S.J.Hotte, L.L.Siu, E.X.Chen, H.W.Hirte, J.Powers, W.Walsh, L.A.Stayner, A.Laughlin, V.Novotny-Diermayr, et al. 2011. Phase I clinical, pharmacokinetic and pharmacodynamic study of SB939, an oral histone deacetylase (HDAC) inhibitor, in patients with advanced solid tumours. Br J Cancer. 104:756–762.
59. M.A.Rivieccio, C.Brochier, D.E.Willis, B.A.Walker, M.A.D'Annibale, K.McLaughlin, A.Siddiq, A.P.Kozikowski, S.R.Jaffrey, J.L.Twiss, et al. 2009. HDAC6 is a target for protection and regeneration following injury in the nervous system. Proc Natl Acad Sci USA. 106:19599–19604.
60. S.Ropero, M.Esteller 2007. The role of histone deacetylases (HDACs) in human cancer. Mol Oncol. 1:19–25.
61. Y.Shao, Z.Gao, P.A.Marks, X.Jiang. 2004. Apoptotic and autophagic cell death induced by histone deacetylase inhibitors. Proc Natl Acad Sci USA. 101:18030–18035.
62. M.V.Swamy, J.M.Patlolla, V.E.Steele, L.Kopelovich, B.S.Reddy, C.V.Rao. 2006. Chemoprevention of familial adenomatous polyposis by low doses of atorvastatin and celecoxib given individually and in combination to APCMin mice. Cancer Res. 66:7370–7377.
63. A.Tampakis, E.C.Tampaki, C.A.Nebiker, G.Kouraklis. 2014. Histone deacetylase inhibitors and colorectal cancer:what is new? Anticancer Agents Med Chem. 14:1220–1227.
64. J.W.Tyner, T.G.Bumm, J.Deininger, L.Wood, K.J.Aichberger, M.M.Loriaux, B.J.Druker, C.J.Burns, E.Fantino, M.W.Deininger. 2010. CYT387, a novel JAK2 inhibitor induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms. Blood. 115:5232–5240.
65. K.Ververis, A.Hiong, T.C.Karagiannis, P.V.Licciardi. 2013. Histone deacetylase inhibitors (HDACIs):multitargeted anticancer agents. Biologics. 7:47–60.
66. O.Witt, H.E.Deubzer, T.Milde, I.Oehme. 2009. HDAC family:what are the cancer relevant targets? Cancer Lett. 277:8–21.
67. W.P.Yong, B.C.Goh, R.A.Soo, H.C.Toh, K.Ethirajulu, J.Wood, V.Novotny-Diermayr, S.C.Lee, W.L.Yeo, D.Chan, et al. 2011. Phase I and pharmacodynamic study of an orally administered novel inhibitor of histone deacetylases, SB939, in patients with refractory solid malignancies. Ann Oncol. 22:2516–2522.
68. C.Z.Zhang, H.T.Zhang, G.G.Chen, P.B.Lai. 2011. Trichostatin A sensitizes HBx-expressing liver cancer cells to etoposide treatment. Apoptosis. 16:683–695.
69. Y.Zhang, D.Reinberg 2001. Transcription regulation by histone methylation:interplay between different covalent modifications of the core histone tails. Genes Dev. 15:2343–2360.